Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Sanofi-aventis
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
A multicenter, multi-national, randomized, double-blind, placebo-controlled, study to assess the efficacy and safety of ciclesonide metered-dose inhaler at 80 μg BID or 40 μg BID for 12 weeks in patients aged 4 to <12 years with persistent asthma
To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg BID or 40 μg BID for 12 weeks in patients aged 4 to <12 years with persistent asthma.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis U.S. Inc
MAJ Il y a 4 ans
A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses
To determine the effect of teriflunomide in reducing the frequency of relapses in subjects with relapsing multiple sclerosis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Aventis Intercontinental - Sanofi-aventis
MAJ Il y a 4 ans
A prospective, randomized, open-label, active-controlled study in adult subjects with acute bacterial sinusitis comparing the clinical efficacy of telithromycin (KETEK®) 800 mg once a day for 5 days versus amoxicillin-clavulanic acid (AUGMENTIN®) 875/125 mg twice a day for 10 days
to demonstrate that the clinical efficacy of Ketek® 800 mg OD for 5 days is noninferior to Augmentin® 875/125 mg BID for 10 days at the test of cure visit (Day 17-21).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
An open-label, randomized, two-arm parallel group study to compare the effects of 4-week QD treatment with lixisenatide or liraglutide on the postprandial plasma glucose in patients with type 2 diabetes not adequately controlled with metformin
To investigate the effects of repeated subcutaneous doses of 20 µg lixisenatide as compared to 1.8 mg liraglutide in reducing postprandial plasma glucose (PPG) assessed as area under the plasma glucos...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
TELI CAP - Telithromycin in children with mild to moderate community-acquired pneumonia
To assess the steady state pharmacokinetics of telithromycin oral suspension (25 mg/kg once a day for 7-10 days), in children 6 months to less than 13 years of age (<13) with community acquired pneumo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
Bioavailability study with two formulations of Clopidogrel in young healthy men
To compare the bioavailabilty of clopidogrel administered as 75 mg Plavix® tablet to that of 75 mg of clopidogrel in drinkable solution, after single oral administration, in fasting state, to normal h...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis U.S. Inc
MAJ Il y a 4 ans
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-daily in the morning regimen (160 μg qd AM) for 16 weeks or in a 160 μg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 μg bid) for 4 weeks, or in an 80 μg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids
To investigate the efficacy, compared to placebo, of ciclesonide at a daily dose of 160 μg administered either in a once-daily in the morning regimen (160 μg qd AM) for 16 weeks or in a 160 μg qd AM r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2